Defining statistical cure in patients with T1 high‐grade non‐muscle‐invasive bladder carcinoma treated with BCG immunotherapy
We found that BCG immunotherapy achieves a statistical cure in select T1HG NMIBC patients, with avoidance of progression to muscle-invasive bladder carcinoma in approximately 70% of cases. The probability of experiencing any adverse oncological event (recurrence, progression or death) is less than 10% among patients who remain event-free for 5 years.
Authors
- Giuseppe Basile (ORCID: https://orcid.org/0000-0002-7227-7821)
- Irene de la Parra (ORCID: https://orcid.org/0000-0002-4064-9133)
- J. Caño-Velasco (ORCID: https://orcid.org/0000-0003-0498-8602)
- Roberto Contieri (ORCID: https://orcid.org/0000-0001-7011-0537)
- Laura S. Mertens (ORCID: https://orcid.org/0000-0003-3317-6427)
- Francesco Soria (ORCID: https://orcid.org/0000-0001-8443-8453)
- Albert Carrión (ORCID: https://orcid.org/0000-0002-4639-1532)
- Pietro Scilipoti (ORCID: https://orcid.org/0009-0007-6126-9889)
- David D‘Andrea (ORCID: https://orcid.org/0000-0003-1625-1077)
- F.J. Burgos Revilla (ORCID: https://orcid.org/0000-0002-0758-5414)
- Paolo Gontero (ORCID: https://orcid.org/0000-0002-9714-6596)
- Luca Afferi (ORCID: https://orcid.org/0000-0002-5472-1933)
- Andrea Gallioli (ORCID: https://orcid.org/0000-0002-3316-5691)
- Javier Aranda (ORCID: https://orcid.org/0000-0002-9000-6670)
- Keiichiro Mori (ORCID: https://orcid.org/0000-0002-6147-6569)
- Benjamin Pradère (ORCID: https://orcid.org/0000-0002-7768-8558)
- Mattia Longoni (ORCID: https://orcid.org/0000-0002-2613-2306)
- Wojciech Krajewski
- Karl H. Tully (ORCID: https://orcid.org/0000-0002-9499-0169)
- A. Artiles Medina (ORCID: https://orcid.org/0000-0003-0930-0344)
- José Luis Rodríguez Elena
- C. Mínguez Ojeda (ORCID: https://orcid.org/0000-0002-4188-3298)
- Ana Sáiz (ORCID: https://orcid.org/0000-0001-7110-450X)
- Oscar Buisán (ORCID: https://orcid.org/0000-0001-6368-249X)
- E. Lopez Perez
- Simone Albisinni (ORCID: https://orcid.org/0000-0001-5529-3064)
- Félix Guerrero‐Ramos (ORCID: https://orcid.org/0000-0002-0767-3465)
- Mario de Angelis (ORCID: https://orcid.org/0009-0008-0494-7839)
- Mario Álvarez‐Maestro (ORCID: https://orcid.org/0000-0003-0705-7643)
- Gautier Marcq (ORCID: https://orcid.org/0000-0002-1806-1448)
- L. Polanco Pujol
- Jeremy Yuen‐Chun Teoh (ORCID: https://orcid.org/0000-0002-9361-2342)
- José Daniel Subiela (ORCID: https://orcid.org/0000-0003-4176-8174)
- Pablo Gajate (ORCID: https://orcid.org/0000-0001-5156-7080)
- Ekaterina Laukhtina (ORCID: https://orcid.org/0000-0002-8953-0272)
- Renate Pichler (ORCID: https://orcid.org/0000-0001-5286-9048)
- Daniel A. González‐Padilla (ORCID: https://orcid.org/0000-0002-5853-8845)
- F. Lozano Palacio
- Andrzej Tukiendorf (ORCID: https://orcid.org/0000-0001-5278-989X)
- Eduardo Albers Acosta (ORCID: https://orcid.org/0000-0002-0091-6209)
- Marco Moschini (ORCID: https://orcid.org/0000-0002-3084-2458)
- V. Gómez Dos Santos (ORCID: https://orcid.org/0000-0003-2968-148X)
- Júlia Aumatell (ORCID: https://orcid.org/0000-0001-7732-0596)
- Javier Taborda
- José Agustín López‐González
- A. Lafuente Puentedura
- A. Fernandez Mardomingo
- Andrea Mari (ORCID: https://orcid.org/0000-0001-9070-5706)
- Francesco Del Giudice (ORCID: https://orcid.org/0000-0003-3865-5988)
- José L. Domínguez-Escrig
- P. Del Olmo Duran
- C.J. Martin
- Franklin Anagua Melendres
Institutions
- Jikei University School of Medicine (JP)
- University of Rome Tor Vergata (IT)
- Centre National de la Recherche Scientifique (FR)
- Humanitas University (IT)
- Innsbruck Medical University (AT)
- Vita-Salute San Raffaele University (IT)
- Inserm (FR)
- University of Opole (PL)
- Chinese University of Hong Kong (HK)
- Universidad de Alcalá (ES)
- Universität Innsbruck (AT)
- Instituto Cajal (ES)
- Policlinico Umberto I (IT)
- Hospital Universitario La Paz (ES)
- Institut Pasteur de Lille (FR)
- McGill University Health Centre (CA)
- Bellvitge University Hospital (ES)
- The Netherlands Cancer Institute (NL)
- Hospital General Universitario Gregorio Marañón (ES)
- Centre Hospitalier Universitaire de Lille (FR)
- Universitätsklinik Marien Hospital Herne (DE)
- Comprehensive Cancer Center Vienna (AT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Hospital Universitario Rey Juan Carlos (ES)
- Hospital Universitario 12 De Octubre (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Luzerner Kantonsspital (CH)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario de La Princesa (ES)
- Clinica Universidad de Navarra (ES)
- Hospital Universitario HM Sanchinarro (ES)
- Puigvert Foundation (ES)
- Center for Special Minimally Invasive and Robotic Surgery (US)
- Roche (Spain) (ES)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Hôpital Claude Huriez (FR)
- Complejo Hospitalario de Cáceres (ES)
- Hospital Universitario Ramón y Cajal (ES)
- IRCCS Humanitas Research Hospital (IT)
- University of Florence (IT)
- Universitat de Barcelona (ES)
- Medical University of Vienna (AT)
- Sapienza University of Rome (IT)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1111/bju.16913
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00